Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2021

View Archived Issues

BioNTech initiates first-in-human study of BNT-151

First-in-human data for ACT-1004-1239

QBW-251 enters phase II for bronchiectasis

NLY-01 exerts neuroprotective effects in model of experimental autoimmune encephalomyelitis

Enrollment opens in phase II study of RO-7017773 for autism spectrum disorder

Diverse populations, long reads give genome insights

Promising interim data presented from SAD portion of MORF-057 phase I program

VBL Therapeutics initiates dosing patients in phase II study of VB-111 in rGBM

Anti-TNF-alpha antibodies presented by Sinocelltech

Bristol Myers Squibb presents new ROR-gammaT agonists

Amgen discovers kinesin-like protein KIF18A inhibitors

Alkermes patents mu-opioid receptor agonists

New Janus kinase inhibitors synthesized at Vimalan Biosciences

New bispecifics capture challenging targets

FDA clears IND application for FX-301 for postoperative pain

Alofanib shows safety and antitumor efficacy in patients with advanced gastric cancer

Myoferlin inhibitor YQ-456 shows efficacy in PDX model of colorectal cancer

FDA agrees to advance VERU-111 into phase III study in COVID-19 patients at high risk for ARDS

FDA issues complete response letter for oral paclitaxel plus encequidar in metastatic breast cancer

First patient dosed in phase II study of OTX-DED for short-term treatment of dry eye disease

Inovio reports phase III data on VGX-3100 to treat HPV-16/18 cervical HSIL

MEDI-1191 demonstrates preliminary antitumor activity in advanced solid tumors

Carna receives CTA clearance for phase I study of BTK inhibitor AS-1763

ADORA2A is a therapeutic target in progressive multiple sclerosis

Merck & Co. withdraws U.S. indication for Keytruda in metastatic SCLC after platinum chemotherapy

Hoth advances site recruitment for first-in-human study of BioLexa for atopic dermatitis

Kymera begins dosing in first-in-human study of KT-474 for atopic dermatitis or HS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...